Linezolid formulations are contraindicated for using in patients who have known hypersensitivity to Linezolid or any of the other product components.
Linezolid is a synthetic, antibacterial agent belonging to a new class of antibiotics, the oxazolidinones, with in vitro activity against Gram positive aerobic bacteria, some Gram positive anaerobic bacteria and certain Gram negative bacteria.
Therefore, Lizid has the potential for interaction with adrenergic and serotonergic agents. Some individuals receiving Lizid may experience a reversible enhancement of the pressor response to indirect acting sympathomimetic agents, vasopressor or dopaminergic agents.
Linezolid formulations are contraindicated for using in patients who have known hypersensitivity to Linezolid or any of the other product components.
Most of the adverse events reported with Lizid were mild to moderate in intensity. The most common adverse events in patients treated with Lizid were diarrhea, headache and nausea. Other adverse events includes oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration.
Pregnancy: Available data with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes
Complete blood counts should be monitored weekly in patients who receive Lizid, particularly in those who receive Lizid for longer than two weeks, those with pre-existing myelosuppression, those receiving concomitant drugs that produce bone marrow suppression or those with a chronic infection who have received previous or concomitant antibiotic therapy.
No cases of overdose have been reported. Symptomatic and supportive care is advised together with maintenance of glomerular filtration.
Lizid is indicated for the treatment of:
